Posts

Novartis drops phase 2 radioligand therapy, but CEO’s commitment to the modality unchanged

on

Chai Discovery raises $400M Series C for AI molecule models used by Lilly, Novartis and Pfizer

on

Novartis Cuts New Jersey Jobs

on

Biopharma bites: Job cuts at Novartis, fresh funding for MeiraGTx and Fore, plus Boehringer's latest deal – 2026 update

on

Novartis to Acquire UK Biotech Myricx Bio for Up to $1.5 Billion to Expand ADC Oncology Pipeline

on

Novartis pays Antares $105M to illuminate undruggable cancer targets

on

Novartis tightens bond with Orionis in up to $1.4B molecular glue deal - Biospace, European Biotechnology, LinkedIn, etc.

on

Sensorion advances hearing loss gene therapy programs

on

Entrada's Stock Craters as DMD Data Underperform Expectations, Handing Advantage to Novartis

on

Novartis to Cut 220 Jobs as Wehr, Germany Site Closes by 2028

on

Novartis Breaks Ground on Flagship North Carolina Manufacturing Hub as Key Milestone in $23B US Expansion

on

Novartis CEO Calls for 'Complete Rethink' on Europe's Drug Pricing Policies

on

Spotlight On: Key Takeaways from Novartis' Q1 2026 Earnings Call

on

Novartis Stands by $5B Pluvicto Goal Despite EU Setback and Bispecific Competition

on

Novartis CEO on Continued Evaluation of In Vivo CAR-T Therapies Without Current Deals

on

Novartis CEO Vas Narasimhan Joins Anthropic's Board

on

Novartis CEO Vas Narasimhan Joins Anthropic Board to Advance Responsible AI in Healthcare

on

Novartis Agrees to Acquire Excellergy for Up to $2 Billion to Bolster Allergy Portfolio with Potential Xolair Successor

on

Novartis Commits $480M to Expand Manufacturing and R&D in China Following AstraZeneca and Lilly

on

Novartis Pays Synnovation $2B Upfront for Breast Cancer Drug SNV4818 as Rivals Compete

on